Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Sinclair Pharma Plc completes share issue raising gross proceeds of £19 million

Reading Time 1 minute read Subscribe



Sinclair Pharma PLC

On 4 October 2010, the shareholders of Sinclair Pharma Plc ("Sinclair Pharma") approved a firm placing and placing and open offer to raise gross proceeds of £19 million. Application was made for the new ordinary shares to be admitted to trading on both the London Stock Exchange's main market for listed securities and on the Eurolist of Euronext, Paris with effect from 6 October 2010.   Sinclair Pharma is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and innovative delivery systems.  Fasken Martineau advised Sinclair Pharma on this transaction with a team comprised of June Paddock, Abayomi Akinjide, Peter Rhodes and Michael Kashis.



    Receive email updates from our team